Active

Kos Biotechnology Partners

General contacts
Investor type

VC

Founded

2024

AUM

-

Location

Athens, New York, United States

Investment Ticket

$10-50 m

Investment Stage

Pre-seed Seed Series A Series B Late Stage (Series C+)

Region of investment

North America Europe
Investor profile last updated: 15 June, 2026

Profile

Kos Biotechnology Partners is a life sciences investment firm with headquarters in New York City and Athens, Greece. It was founded by Dr. Simos Simeonidis, who has extensive experience in biomedical research and financial analysis, and Alex Tzoukas, an expert in healthcare investment banking and private equity. The firm is managed alongside Nikos Kostaras, who brings operational expertise from his time at IQVIA. The team is known for building a bridge between the US and European biopharma ecosystems and leverages a network of advisors from the Greek diaspora to scale their portfolio companies globally.

Kos focuses on high-impact investments within the life sciences sector, specifically targeting biotech/novel therapeutics, pharma services, and tech-enabled sectors that integrate AI and modern defense applications. With a flexible approach to deploying capital across all stages of company development, they invest from company formation through Series C. The Global Life Sciences Fund currently has $123M in commitments, backed by institutions like the Hellenic Development Bank of Investments and other global family offices.

Notable investments by Kos include leading a financing round for Epikast, a tech-enabled pharma services provider, and investing strategically in a biotechnology company based in San Francisco. Their portfolio is poised to grow with additional investments planned for completion within the year.

Industry

Biotechnology Healthcare Services Pharmaceuticals AI HealthTech

Kos Biotechnology Partners Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region 		Size AUM Launch date
Global Life Sciences Fund
Venture Capital (VC)
Biotechnology
Pharmaceuticals
HealthTech
Pre-seed
Seed
Series A
Series B
Late Stage (Series C+)
North America
Europe
$10-50 m
$123 M
June 2026

Contacts

Name
Title
Email
Social Networks
Upgrade to see contacts
avatar
lL9R1PESzZdc07hM lL9R1PESzZdc07hM
lL9R1PESzZdc07hM
[email protected]
linkedin twitter
avatar
lL9R1PESzZdc07hM lL9R1PESzZdc07hM
lL9R1PESzZdc07hM
[email protected]
linkedin twitter
avatar
lL9R1PESzZdc07hM lL9R1PESzZdc07hM
lL9R1PESzZdc07hM
[email protected]
linkedin twitter
avatar
lL9R1PESzZdc07hM lL9R1PESzZdc07hM
lL9R1PESzZdc07hM
[email protected]
linkedin twitter
avatar
lL9R1PESzZdc07hM lL9R1PESzZdc07hM
lL9R1PESzZdc07hM
[email protected]
linkedin twitter
Investment-team contacts for Kos Biotechnology Partners — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Kos Biotechnology Partners

Kos Biotechnology Partners is a venture capital firm. It backs companies at Pre-seed, Seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.
Kos Biotechnology Partners is located in Athens, New York, United States.
Kos Biotechnology Partners was founded in 2024.
Kos Biotechnology Partners invests in companies and startups in Biotechnology, Healthcare Services, Pharmaceuticals, AI, HealthTech.
Kos Biotechnology Partners invests in companies and startups in North America, Europe.
Kos Biotechnology Partners invests in companies and startups at Pre-seed, Seed, Series A, Series B, Late Stage (Series C+).
Kos Biotechnology Partners usually invests $10-50 m on average.
Kos Biotechnology Partners last fund was created/launched in 2026-06-15
Kos Biotechnology Partners can be reached through its website kosbp.com and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Kos Biotechnology Partners — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Kos Biotechnology Partners directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 15 June, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.